-+ 0.00%
-+ 0.00%
-+ 0.00%

SERNOVA AND SERAXIS CLOSE US$11.2 MILLION FINANCING TO FUND MERGER TO BECOME BETANOVA BIOTHERAPEUTICS AND ADVANCE TYPE 1 DIABETES CELL THERAPY INTO NEAR TERM PHASE 1/2 CLINICAL TRIAL

Reuters·10/05/2026 11:02:59